Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$53.30

-0.1401 (-0.26%)

14:07
04/21/17
04/21
14:07
04/21/17
14:07

Bristol-Myers receives 'positive' CHMP opinion on Opdivo approval

Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Opdivo is the first and only PD-1 immune checkpoint inhibitor for the treatment of patients with previously treated mUC to receive a positive CHMP opinion. Opdivo is already approved by the EC for six indications in four distinct tumor types. "We view the CHMP recommendation of Opdivo for previously treated locally advanced or metastatic urothelial carcinoma as an important milestone for the patients. Bristol-Myers Squibb looks forward to collaborating with the European Commission as it considers this potential new indication for Opdivo," said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

BMY Bristol-Myers
$53.30

-0.1401 (-0.26%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
04/03/17
LEER
04/03/17
NO CHANGE
Target $141
LEER
Outperform
Incyte price target raised to $141 from $130 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $141 from $130 as he sees epacadostat better positioned in the emerging IO combination landscape. The analyst notes that the company and Bristol-Myers (BMY) have announced that both companies will advance the combination of Opdivo and epacadostat into several registration trials in 2017. He reiterates an Outperform rating on Incyte's shares.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

CCL

Carnival

$65.87

-0.565 (-0.85%)

, CUK

Carnival plc

$65.87

-0.72 (-1.08%)

10:21
06/22/17
06/22
10:21
06/22/17
10:21
Hot Stocks
Carnival says realizing 'strength' in booking trends across core products »

Says on track to realize…

CCL

Carnival

$65.87

-0.565 (-0.85%)

CUK

Carnival plc

$65.87

-0.72 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

WLL

Whiting Petroleum

$5.27

0.095 (1.84%)

10:20
06/22/17
06/22
10:20
06/22/17
10:20
Options
Call buyer tied to hedge in Whiting Petroleum appears closing »

Call buyer tied to hedge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

JBL

Jabil Circuit

$29.00

-0.1 (-0.34%)

, MMP

Magellan Midstream

$68.33

0.395 (0.58%)

10:19
06/22/17
06/22
10:19
06/22/17
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

JBL

Jabil Circuit

$29.00

-0.1 (-0.34%)

MMP

Magellan Midstream

$68.33

0.395 (0.58%)

AVB

AvalonBay

$193.47

-1.09 (-0.56%)

AQMS

Aqua Metals

$11.95

-0.36 (-2.92%)

TACO

Del Taco

$13.87

0.14 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$61.87

2.13 (3.57%)

, DFT

DuPont Fabros

$64.48

-0.17 (-0.26%)

10:19
06/22/17
06/22
10:19
06/22/17
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

KMX

CarMax

$61.87

2.13 (3.57%)

DFT

DuPont Fabros

$64.48

-0.17 (-0.26%)

TSM

TSMC

$36.73

0.02 (0.05%)

SAND

Sandstorm Gold

$3.54

-0.0921 (-2.54%)

DAN

Dana Holding

$21.47

-0.35 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

ORCL

Oracle

$50.78

4.45 (9.61%)

, LUV

Southwest

$61.53

0.495 (0.81%)

10:19
06/22/17
06/22
10:19
06/22/17
10:19
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

ORCL

Oracle

$50.78

4.45 (9.61%)

LUV

Southwest

$61.53

0.495 (0.81%)

ANF

Abercrombie & Fitch

$12.08

0.029 (0.24%)

KMX

CarMax

$61.87

2.13 (3.57%)

EAT

Brinker

$38.06

1.13 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 30

    Jun

  • 07

    Jul

ATUS

Altice USA

10:18
06/22/17
06/22
10:18
06/22/17
10:18
Syndicate
Altice USA opens at $31.60, IPO priced at $30 per share »

Altice USA (ATUS) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

10:17
06/22/17
06/22
10:17
06/22/17
10:17
General news
Forcing Pelosi out would be 'very bad' for Republicans, Trump says »

President Donald Trump…

$NSD

NASDAQ Market Internals

10:17
06/22/17
06/22
10:17
06/22/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
06/22/17
06/22
10:16
06/22/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
06/22/17
06/22
10:15
06/22/17
10:15
General news
U.S. leading index rose 0.3% to 127.0 in May, an all time high »

U.S. leading index rose…

10:15
06/22/17
06/22
10:15
06/22/17
10:15
General news
Breaking General news story  »

Week of 6/16 EIA Natural…

SINA

SINA

$91.93

3.5 (3.96%)

, WB

Weibo

$76.96

2.88 (3.89%)

10:14
06/22/17
06/22
10:14
06/22/17
10:14
Hot Stocks
Chinese internet stocks fall following report of streaming ban »

Shares of Chinese…

SINA

SINA

$91.93

3.5 (3.96%)

WB

Weibo

$76.96

2.88 (3.89%)

FENG

Phoenix New Media

$2.69

-0.06 (-2.18%)

YY

YY

$58.98

0.89 (1.53%)

MOMO

Momo

$38.70

0.81 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ANF

Abercrombie & Fitch

$12.19

0.14 (1.16%)

10:10
06/22/17
06/22
10:10
06/22/17
10:10
Upgrade
Abercrombie & Fitch rating change  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.43

0.59 (5.44%)

10:10
06/22/17
06/22
10:10
06/22/17
10:10
Options
5K Horizon Pharm Jan 15 calls opened for 89c when bid-ask was 45 to 90c »

5K Horizon Pharm Jan 15…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

10:08
06/22/17
06/22
10:08
06/22/17
10:08
Syndicate
Altice USA indicated to open at $31.50, IPO priced at $30 »

Altice USA (ATUS) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CVM

CEL-SCI

$1.80

0.11 (6.51%)

10:08
06/22/17
06/22
10:08
06/22/17
10:08
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI »

Cel Sci trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$17.93

0.15 (0.84%)

10:07
06/22/17
06/22
10:07
06/22/17
10:07
Technical Analysis
Technical View: Twitter bounces higher for second session »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

SGBX

SG Blocks

10:06
06/22/17
06/22
10:06
06/22/17
10:06
Syndicate
Breaking Syndicate news story on SG Blocks »

SG Blocks opens at $4.75,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

IGLD

Internet Gold

10:06
06/22/17
06/22
10:06
06/22/17
10:06
Hot Stocks
Breaking Hot Stocks news story on Internet Gold »

Internet Gold trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$121.52

-5.59 (-4.40%)

10:04
06/22/17
06/22
10:04
06/22/17
10:04
Technical Analysis
Technical View: Accenture trades near lows of the day »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

GM

General Motors

$34.06

-0.07 (-0.21%)

10:04
06/22/17
06/22
10:04
06/22/17
10:04
Hot Stocks
GM reports 'successful' conclusion of three-year consent order with NHTSA »

General Motors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

10:01
06/22/17
06/22
10:01
06/22/17
10:01
General news
Leading Indicators data reported »

May Leading Indicators up…

IGLD

Internet Gold

10:01
06/22/17
06/22
10:01
06/22/17
10:01
Hot Stocks
Breaking Hot Stocks news story on Internet Gold »

Internet Gold trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$17.85

0.0699 (0.39%)

10:01
06/22/17
06/22
10:01
06/22/17
10:01
Hot Stocks
Twitter, Sela Sport announce live streaming partnership »

Twitter and Sela Sport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

QQQ

PowerShares QQQ Trust

$140.74

1.38 (0.99%)

10:00
06/22/17
06/22
10:00
06/22/17
10:00
Options
Bullish three-way spread in PowerShares QQQ »

Bullish three-way spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.